Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 11% Improvement Relative Risk Hall et al. HCQ for COVID-19 ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 505 patients in the USA Lower mortality with HCQ (not stat. sig., p=0.31) Hall et al., The Annals of Thoracic Surgery, doi:10.1016/j.athoracsur.2022.01.043 Favors HCQ Favors control
Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival
Hall et al., The Annals of Thoracic Surgery, doi:10.1016/j.athoracsur.2022.01.043
Hall et al., Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival, The Annals of Thoracic Surgery, doi:10.1016/j.athoracsur.2022.01.043
Feb 2022   Source   PDF  
  All Studies   Meta
Retrospective 505 ECMO patients showing no significant difference in mortality in unadjusted results. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 11.2% lower, RR 0.89, p = 0.31, treatment 31 of 56 (55.4%), control 280 of 449 (62.4%), NNT 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hall et al., 18 Feb 2022, retrospective, USA, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival Celeste A. Hall, Jeffrey P. Jacobs, MD, Alfred H. Stammers, MSA, James D. St. Louis, MD, J.W. Awori Hayanga, MD, Michael S. Firstenberg, MD, Linda B. Mongero, CCP, Eric A. Tesdahl, PhD, Keshava Rajagopal, MD, PhD, Faisal H. Cheema, MD, Kirti Patel, CCP, Tom Coley, CCP, Anthony K. Sestokas, PhD, Marvin J. Slepian, MD, Vinay Badhwar, MD PII: S0003-4975(22)00198-9 DOI: Reference: ATS 36012 To appear in: The Annals of Thoracic Surgery Received Date: 7 November 2021 Revised Date: 18 December 2021 Accepted Date: 25 January 2022 Please cite this article as: Hall CA, Jacobs JP, Stammers AH, St. Louis JD, Hayanga JWA, Firstenberg MS, Mongero LB, Tesdahl EA, Rajagopal K, Cheema FH, Patel K, Coley T, Sestokas AK, Slepian MJ, Badhwar V, Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival The Annals of Thoracic Surgery (2022), doi: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 by The Society of Thoracic Surgeons Jo na ur re lP ro -p of Jacobs Page 1 of 16 Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival Running Head: ECMO and COVID-19 aCeleste A. Hall, a,bJeffrey P. Jacobs, MD, bAlfred H. Stammers, MSA, cJames D. St. Louis, MD, dJ.W. Awori Hayanga, MD, eMichael S Firstenberg, MD, bLinda B. Mongero, CCP, bEric A. Tesdahl, PhD, fKeshava Rajagopal, MD, PhD, f,gFaisal H. Cheema, MD, bKirti Patel, CCP, bTom Coley, CCP, of bAnthony K. Sestokas, PhD, hMarvin J. Slepian, MD, dVinay Badhwar, MD aUniversity of Florida, Gainesville, FL; bMedical Department, SpecialtyCare, Inc., Nashville, TN ; ro cChildren Hospital of Georgia, Augusta, Georgia; dWest Virginia University, Morgantown, WV; eSt -p Elizabeth Medical Center, Appleton, Wisconsin; fUniversity of Houston, Houston, TX; gHCA Research lP re Institute, Nashville, TN; hUniversity of Arizona, Tucson, AZ ur na Presented at the Sixty-eighth Annual Meeting of the Southern Thoracic Surgical Association, Atlanta, GA, Nov 3-6, 2021. Keywords: Extracorporeal Membrane Oxygenation, Coronavirus, COVID-19, Pulmonary failure, Jo acute respiratory distress syndrome Words: 4,496/4500 Corresponding Author: Jeffrey P. Jacobs, University of Florida, 1600 SW Archer Rd, Gainesville, Florida; Jacobs Page 2 of 16 Abstract Background: We reviewed our experience with 505 patients with confirmed COVID-19 supported with ECMO at 45 hospitals and estimated risk factors for mortality. Methods: A multi-institutional database was created and utilized to assess all patients with COVID-19 who were supported with ECMO. A Bayesian mixed-effects logistic regression model was estimated to assess the effect on survival of days between COVID-19..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop